Latest Breaking News On - Douglas flora - Page 1 : vimarsana.com

St. Elizabeth Healthcare to open doors of new Cancer Center-Dearborn in Southeastern Indiana - NKyTribune

St. Elizabeth Healthcare will officially open the doors of the St. Elizabeth Cancer Center-Dearborn on Monday, April 29, providing cutting-edge cancer care and easier access to cancer screenings, prev

Exploring the role of artificial intelligence in early cancer detection

Top 5 Sessions, Interviews From the ACCC 50th Annual Meeting & Cancer Center Business Summit

The ACCC 50th Annual Meeting & Cancer Center Business Summit is taking place in Washington, DC from February 28 to March 1.

St. Elizabeth's Dr. Flora discusses role of Artificial Intelligence in medicine, especially cancer treatment - NKyTribune

By Patricia A. ScheyerNKyTribune reporterWith Artificial Intelligence bursting onto the horizon, people are scrambling to see how it fits in various fields, especially the medical field. The sub

Evaluating Performance of AI-Based Large Language Models in Radiation Oncology

Evaluating AI-based nodal contouring in head and neck cancer

Evaluating the performance of AI-based large language models in radiation oncology

St.E.'s Dr. Doug Flora sees 'good and bad' in latest cancer data; good is fewer deaths, earlier treatments - NKyTribune

By Patricia A. ScheyerNKyTribune reporterNew cancer cases in America have passed a major milestone -- 2 million new cases are projected to be diagnosed in 2024.That could be bad news, or it

Assessing the Promise of AI in Oncology: Looking to the Future

In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.

Assessing the Promise of AI in Oncology: Matching Patients With Clinical Trials

In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.